JIC
MRNA icon

Johnson Investment Counsel’s Moderna MRNA Stock Holding History

Johnson Investment Counsel’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,433
Closed -$527K – 681
2023
Q1 		$527K Buy
3,433
+1,414
+70% +$233K 0.01% 449
2022
Q4 		$363K Sell
2,019
-103
-5% -$16.8K ﹤0.01% 514
2022
Q3 		$251K Buy
2,122
+99
+5% +$15K ﹤0.01% 567
2022
Q2 		$289K Hold
2,023
– – ﹤0.01% 554
2022
Q1 		$348K Sell
2,023
-1,018
-33% -$171K ﹤0.01% 546
2021
Q4 		$772K Buy
3,041
+107
+4% +$31.3K 0.01% 383
2021
Q3 		$1.13M Buy
2,934
+104
+4% +$38.4K 0.02% 324
2021
Q2 		$665K Sell
2,830
-15
-0.5% -$2.68K 0.01% 384
2021
Q1 		$373K Buy
2,845
+150
+6% +$21.7K 0.01% 475
2020
Q4 		$282K Sell
2,695
-2,185
-45% -$221K ﹤0.01% 506
2020
Q3 		$345K Buy
+4,880
New +$340K 0.01% 445

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Johnson Investment Counsel's MRNA Position: Q2 2023 in Review

Johnson Investment Counsel sold out of Moderna (MRNA) in Q2 2023, closing a stake of 3,433 shares — an estimated $527K sold.

Johnson Investment Counsel first reported a position in MRNA in Q3 2020 and held it in 11 quarters. The position peaked at $1.13M in Q3 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Johnson Investment Counsel reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Johnson Investment Counsel sold 3,433 Moderna shares in Q2 2023, an estimated $527K.
  • Johnson Investment Counsel first reported a position in Moderna in Q3 2020 and held it in 11 quarters.
  • Johnson Investment Counsel's Moderna position peaked at $1.13M in Q3 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Johnson Investment Counsel's 13F filing for Q2 2023, filed 10 Aug 2023.